CytoMed Therapeutics Limited
NASDAQ: GDTC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Chee Kong Choo
- Employees
- 43
- Headquarters
- Singapore, Singapore
- IPO year
- 2023
- Market cap
- $11.7M
- Website
- https://w2.cytomed.sg
Loading GDTC…
Loading profile data…Frequently asked questions about GDTC
What does CytoMed Therapeutics Limited (GDTC) do?
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are...
Where does GDTC trade?
CytoMed Therapeutics Limited (GDTC) trades on the NASDAQ Capital Market.
What sector is GDTC in?
CytoMed Therapeutics Limited (GDTC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CytoMed Therapeutics Limited?
Chee Kong Choo is the chief executive officer of CytoMed Therapeutics Limited (GDTC).
Where is CytoMed Therapeutics Limited headquartered?
CytoMed Therapeutics Limited is headquartered in Singapore.
Does GDTC pay a dividend?
CytoMed Therapeutics Limited (GDTC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GDTC go public?
CytoMed Therapeutics Limited (GDTC) completed its initial public offering in 2023.